NM + MTI + OXA

NM + MTI + OXA is a combination therapy consisting of three agents, typically used in oncology research and clinical trials. The components are: - NM (Nimustine): An alkylating agent of the nitrosourea class, primarily used for its cytotoxic effects on tumor cells by inducing DNA cross-linking and strand breaks. - MTI (Mitomycin): An antitumor antibiotic that acts as an alkylating agent, causing DNA cross-linking and inhibiting DNA synthesis. - OXA (Oxaliplatin): A platinum-based chemotherapeutic that forms DNA adducts, leading to inhibition of DNA replication and transcription. This combination is investigated for synergistic antineoplastic activity in various solid tumors. Each component has a distinct mechanism targeting cancer cell proliferation through direct interaction with cellular DNA.